Intravenous naftidrofuryl for critical limb ischaemia

Smith, F. B.; Bradbury, Andrew W.; Fowkes, Gerry

doi:10.1002/14651858.cd002070.pub2

Cited by 12 publications

(4 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When revascularization procedures have failed or for whom revascularization is not technically possible, particularly when amputation is the only alternative, a category of drugs called vasoactives could be one of the best alternatives (Smith, Bradbury, & Fowkes, 2012). Also, because there is a high incidence of coronary events and stroke in patients with peripheral arterial disease, the antiplatelet therapy has been recommended to minimize vascular events and increase survival of patients (Baigent et al, 2009;Committee, 1996).…”

Section: Pharmacological Approach For CLI Treatmentmentioning

confidence: 99%

Critical limb ischemia: Current and novel therapeutic strategies

Hassanshahi

Khabbazi

Peymanfar

et al. 2019

Journal Cellular Physiology

View full text Add to dashboard Cite

Critical limb ischemia (CLI) is the advanced stage of peripheral artery disease spectrum and is defined by limb pain or impending limb loss because of compromised blood flow to the affected extremity. Current conventional therapies for CLI include amputation, bypass surgery, endovascular therapy, and pharmacological approaches. Although these conventional therapeutic strategies still remain as the mainstay of treatments for CLI, novel and promising therapeutic approaches such as proangiogenic gene/protein therapies and stem cell‐based therapies have emerged to overcome, at least partially, the limitations and disadvantages of current conventional therapeutic approaches. Such novel CLI treatment options may become even more effective when other complementary approaches such as utilizing proper bioscaffolds are used to increase the survival and engraftment of delivered genes and stem cells. Therefore, herein, we address the benefits and disadvantages of current therapeutic strategies for CLI treatment and summarize the novel and promising therapeutic approaches for CLI treatment. Our analyses also suggest that these novel CLI therapeutic strategies show considerable advantages to be used when current conventional methods have failed for CLI treatment.

show abstract

Section: Pharmacological Approach For CLI Treatmentmentioning

confidence: 99%

Critical limb ischemia: Current and novel therapeutic strategies

Hassanshahi

Khabbazi

Peymanfar

et al. 2019

Journal Cellular Physiology

View full text Add to dashboard Cite

show abstract

“…[33] Use of vasodilators such as iloprost (prostanoids) or naftidrofuryl has also been tried but with variable results. [34] Cilastazol (phosphodiesterase III inhibitor having antiplatelet, vasodilator, and antimitogenic properties) has been shown to favorably increase skin perfusion pressure and wound healing in patients with CLI. [35] Use of oral cilostazol (dosage of 100 mg twice daily), in addition to best medical therapy has resulted in improvement in nearly a quarter of patients with nonreconstructable CLI; however, further studies are required to adequately evaluate its role in these patients.…”

Section: Management Optionsmentioning

confidence: 99%

Current review with evolving management strategies in critical limb ischemia

Sharma

2019

Indian Journal of Radiology and Imaging

View full text Add to dashboard Cite

Critical limb ischemia represents the end stage of peripheral artery disease, which is associated with impaired quality of life and considerable morbidity and mortality. Economical impact of the disease is huge with a substantial burden on patients, healthcare providers, and resources. Varied therapeutic strategies have been employed in the management of these patients. These patients usually have complex multilevel occlusive arteriopathy with significant comorbidities, rendering surgical interventions undesirable in many cases. Recent therapeutic advances with evolving endovascular techniques and gene or cell-based therapies have the potential to dramatically change the therapeutic outlook in these patients.

show abstract

“…Chronic lower limb ischemia has a global prevalence of approximately 202 million, making it one of the most common causes of presentation to the vascular surgeon [1]. An estimated 25% of these patients will develop critical limb ischemia (CLI) [2]. The Trans-Atlantic Society of Cardiovascular Surgery (TASC) defines critical limb ischemia as a chronic process characterized by the presence of ischemic ulcer necrosis or rest pain, limb-threatening ischemia (necessitating amputation within six months), as well as certain specific ankle and toe pressure thresholds [3].…”

Section: Introductionmentioning

confidence: 99%

Revascularization Techniques for Limb Salvage in Critical Limb Ischemia: A Single Institutional Study From Pakistan

Kazmi

Soomro

Ansar

2022

Cureus

View full text Add to dashboard Cite

Objectives: The study aimed to determine the frequency of successful limb salvage in patients presenting with critical limb ischemia utilizing the available revascularization modalities. This descriptive cross-sectional study was conducted in the Department of General Surgery, Shifa International Hospital, Islamabad, from April 2017 to August 2017. Methodology: A total of 96 patients with critical limb ischemia requiring urgent surgery for limb salvage were included in our study. Patients who had undergone previous surgeries for limb ischemia involving the same limb, had concurrent venous disease, or suffered from acute limb ischemia were excluded. All patients underwent either endoscopic angioplasty or bypass surgery. All patients were followed up for six months for the success of limb salvage and the requirement for amputation. Data were analyzed by SPSS version 26.0 (Armonk, NY: IBM Corp.). Results: Our patients had a mean age of 62.03±8.46 years, of whom 63 (65.6%) were men. A total of 47 (49.0%) patients required surgery for a non-healing ulcer, while 49 (51.0%) had resting leg pain. In 55 (57.3%) patients, bypass surgery was performed, while 35 (36.5%) underwent endoscopic angioplasty. The remaining six (6.2%) patients received a combination of both procedures. Limb salvage was successful in 78 (81.3%) patients. There was no difference between outcomes across gender (p=0.122), nor was there any difference in outcome between bypass surgery and endoscopic angioplasty (p=0.665). Conclusion: Encouraging results can be obtained in treatment of critical limb ischemia if revascularization techniques are utilized prudently in a time-effective manner and individualized to each patient's requirements.

show abstract

Intravenous naftidrofuryl for critical limb ischaemia

Cited by 12 publications

References 10 publications

Critical limb ischemia: Current and novel therapeutic strategies

Critical limb ischemia: Current and novel therapeutic strategies

Current review with evolving management strategies in critical limb ischemia

Revascularization Techniques for Limb Salvage in Critical Limb Ischemia: A Single Institutional Study From Pakistan

Contact Info

Product

Resources

About